Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 11,100 shares, a growth of 7.8% from the February 14th total of 10,300 shares. Based on an average trading volume of 4,700 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.9% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Acorda Therapeutics in a research report on Monday, March 11th. They set a “buy” rating for the company.
Read Our Latest Stock Analysis on ACOR
Institutional Trading of Acorda Therapeutics
Acorda Therapeutics Stock Down 4.2 %
ACOR opened at $12.40 on Monday. The company has a debt-to-equity ratio of 3.07, a current ratio of 1.59 and a quick ratio of 1.21. The business has a 50 day simple moving average of $14.90 and a 200-day simple moving average of $13.15. The stock has a market capitalization of $15.38 million, a P/E ratio of -0.72 and a beta of 1.41. Acorda Therapeutics has a 12 month low of $8.98 and a 12 month high of $24.20.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
Featured Articles
- Five stocks we like better than Acorda Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
- Compound Interest and Why It Matters When Investing
- 3 Large-Cap Stocks Buying Back Shares Aggressively
- Technology Stocks Explained: Here’s What to Know About Tech
- Kohl’s Makes Steady Inventory Improvements. Will Buyers Step In?
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.